West Pharmaceutical Services Inc (WST)

$317.92

+1.58

(+0.5%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $313.90
    $319.48
    $317.92
    downward going graph

    1.26%

    Downside

    Day's Volatility :1.75%

    Upside

    0.49%

    downward going graph
  • $310.00
    $415.28
    $317.92
    downward going graph

    2.49%

    Downside

    52 Weeks Volatility :25.35%

    Upside

    23.44%

    downward going graph

Returns

PeriodWest Pharmaceutical Services IncSector (Health Care)S&P500
3 Months
-15.3%
6.4%
10.8%
6 Months
-8.41%
6.0%
13.7%
1 Year
-15.74%
8.5%
21.4%
3 Years
-13.6%
14.6%
26.3%

Highlights

Market Capitalization
23.2B
Book Value
$36.72
Dividend Share
0.78
Dividend Yield
0.25%
Earnings Per Share (EPS)
7.59
PE Ratio
41.68
PEG Ratio
6.72
Wall Street Target Price
401.85
Profit Margin
19.42%
Operating Margin TTM
18.06%
Return On Assets TTM
11.4%
Return On Equity TTM
20.84%
Revenue TTM
2.9B
Revenue Per Share TTM
39.55
Quarterly Revenue Growth YOY
-3.0%
Gross Profit TTM
1.1B
EBITDA
809.6M
Diluted Eps TTM
7.59
Quarterly Earnings Growth YOY
-0.16
EPS Estimate Current Year
7.76
EPS Estimate Next Year
9.05
EPS Estimate Current Quarter
1.26
EPS Estimate Next Quarter
1.99

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for West Pharmaceutical Services Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.4%

Current $317.92
Target $401.85

Company Financials

FY18Y/Y Change
Revenue
1.7B
↑ 7.4%
Net Income
206.9M
↑ 37.29%
Net Profit Margin
12.05%
↑ 2.63%
FY19Y/Y Change
Revenue
1.8B
↑ 7.13%
Net Income
241.7M
↑ 16.82%
Net Profit Margin
13.14%
↑ 1.09%
FY20Y/Y Change
Revenue
2.1B
↑ 16.69%
Net Income
346.2M
↑ 43.24%
Net Profit Margin
16.13%
↑ 2.99%
FY21Y/Y Change
Revenue
2.8B
↑ 31.89%
Net Income
661.8M
↑ 91.16%
Net Profit Margin
23.37%
↑ 7.24%
FY22Y/Y Change
Revenue
2.9B
↑ 1.95%
Net Income
585.9M
↓ 11.47%
Net Profit Margin
20.3%
↓ 3.07%
FY23Y/Y Change
Revenue
2.9B
↑ 2.18%
Net Income
593.4M
↑ 1.28%
Net Profit Margin
20.12%
↓ 0.18%
Q4 FY22Q/Q Change
Revenue
708.7M
↑ 3.17%
Net Income
103.0M
↓ 14.59%
Net Profit Margin
14.53%
↓ 3.03%
Q1 FY23Q/Q Change
Revenue
716.6M
↑ 1.11%
Net Income
140.0M
↑ 35.92%
Net Profit Margin
19.54%
↑ 5.01%
Q2 FY23Q/Q Change
Revenue
753.8M
↑ 5.19%
Net Income
155.1M
↑ 10.79%
Net Profit Margin
20.58%
↑ 1.04%
Q3 FY23Q/Q Change
Revenue
747.4M
↓ 0.85%
Net Income
161.3M
↑ 4.0%
Net Profit Margin
21.58%
↑ 1.0%
Q4 FY23Q/Q Change
Revenue
732.0M
↓ 2.06%
Net Income
137.0M
↓ 15.07%
Net Profit Margin
18.72%
↓ 2.86%
Q1 FY24Q/Q Change
Revenue
695.4M
↓ 5.0%
Net Income
115.3M
↓ 15.84%
Net Profit Margin
16.58%
↓ 2.14%
FY18Y/Y Change
Total Assets
1.6B
↓ 14.52%
Total Liabilities
196.1M
↓ 0.46%
FY19Y/Y Change
Total Assets
2.3B
↑ 47.04%
Total Liabilities
768.2M
↑ 291.74%
FY20Y/Y Change
Total Assets
2.8B
↑ 19.32%
Total Liabilities
939.3M
↑ 22.27%
FY21Y/Y Change
Total Assets
3.3B
↑ 18.61%
Total Liabilities
978.4M
↑ 4.16%
FY22Y/Y Change
Total Assets
3.6B
↑ 9.14%
Total Liabilities
931.9M
↓ 4.75%
FY23Y/Y Change
Total Assets
3.8B
↑ 5.88%
Total Liabilities
948.5M
↑ 1.78%
Q4 FY22Q/Q Change
Total Assets
3.6B
↑ 9.04%
Total Liabilities
931.9M
↑ 10.15%
Q1 FY23Q/Q Change
Total Assets
3.7B
↑ 2.95%
Total Liabilities
947.4M
↑ 1.66%
Q2 FY23Q/Q Change
Total Assets
3.7B
↓ 1.45%
Total Liabilities
922.9M
↓ 2.59%
Q3 FY23Q/Q Change
Total Assets
3.8B
↑ 2.32%
Total Liabilities
886.5M
↓ 3.94%
Q4 FY23Q/Q Change
Total Assets
3.8B
↑ 1.99%
Total Liabilities
948.5M
↑ 6.99%
Q1 FY24Q/Q Change
Total Assets
3.6B
↓ 5.93%
Total Liabilities
921.7M
↓ 2.83%
FY18Y/Y Change
Operating Cash Flow
288.6M
↑ 9.61%
Investing Cash Flow
-100.8M
↓ 24.55%
Financing Cash Flow
-80.7M
↓ 25.96%
FY19Y/Y Change
Operating Cash Flow
367.2M
↑ 27.23%
Investing Cash Flow
-228.0M
↑ 126.19%
Financing Cash Flow
-36.8M
↓ 54.4%
FY20Y/Y Change
Operating Cash Flow
472.5M
↑ 28.68%
Investing Cash Flow
-179.5M
↓ 21.27%
Financing Cash Flow
-137.1M
↑ 272.55%
FY21Y/Y Change
Operating Cash Flow
584.0M
↑ 23.6%
Investing Cash Flow
-253.1M
↑ 41.0%
Financing Cash Flow
-168.1M
↑ 22.61%
FY22Y/Y Change
Operating Cash Flow
724.0M
↑ 23.97%
Investing Cash Flow
-288.2M
↑ 13.87%
Financing Cash Flow
-293.6M
↑ 74.66%
Q4 FY22Q/Q Change
Operating Cash Flow
230.8M
↑ 36.65%
Investing Cash Flow
-94.8M
↑ 60.41%
Financing Cash Flow
-9.5M
↓ 87.37%
Q1 FY23Q/Q Change
Operating Cash Flow
138.1M
↓ 40.16%
Investing Cash Flow
-82.1M
↓ 13.4%
Financing Cash Flow
-71.0M
↑ 647.37%
Q2 FY23Q/Q Change
Operating Cash Flow
169.2M
↑ 22.52%
Investing Cash Flow
-82.1M
↑ 0.0%
Financing Cash Flow
-176.8M
↑ 149.01%
Q3 FY23Q/Q Change
Operating Cash Flow
230.1M
↑ 35.99%
Investing Cash Flow
-259.9M
↑ 216.57%
Financing Cash Flow
-22.3M
↓ 87.39%

Technicals Summary

Sell

Neutral

Buy

West Pharmaceutical Services Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-4.46%
-8.41%
-15.74%
-13.6%
158.45%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
5.19%
21.07%
35.15%
44.46%
154.91%
Resmed Inc.
Resmed Inc.
-1.3%
14.89%
-7.63%
-20.45%
64.31%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.17%
-2.18%
-12.88%
-6.34%
-8.62%
Alcon Ag
Alcon Ag
1.0%
13.85%
6.76%
29.31%
50.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
41.68
41.68
6.72
7.76
0.21
0.11
0.0
36.72
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
71.38
71.38
7.13
6.29
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
31.37
31.37
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
49.52
49.52
1.34
13.04
0.05
0.03
0.02
88.74
Alcon Ag
Alcon Ag
42.7
42.7
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.2B
158.45%
41.68
19.42%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$147.6B
154.91%
71.38
27.16%
Resmed Inc.
Resmed Inc.
Buy
$30.0B
64.31%
31.37
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.0B
-8.62%
49.52
6.76%
Alcon Ag
Alcon Ag
Buy
$44.5B
50.52%
42.7
10.96%

Insights on West Pharmaceutical Services Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 753.8M → 695.4M (in $), with an average decrease of 2.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 161.3M → 115.3M (in $), with an average decrease of 15.5% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 35.2% return, outperforming this stock by 50.9%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 44.5% return, outperforming this stock by 58.1%

Institutional Holdings

  • Vanguard Group Inc

    12.27%
  • BlackRock Inc

    10.38%
  • Bank of New York Mellon Corp

    4.52%
  • State Street Corporation

    4.42%
  • Franklin Resources Inc

    3.40%
  • Apg All Pensions Group

    3.21%

Corporate Announcements

  • West Pharmaceutical Services Inc Dividends March,2024

    In the quarter ending March,2024. West Pharmaceutical Services Inc has declared dividend of $0.2

    Read More

Company Information

west works side-by-side with healthcare partners from concept to the patient, designing and manufacturing packaging and delivery systems that promote efficiency, reliability and safety. west leads the way with cutting-edge technologies and quality systems, a thorough understanding of global regulatory compliance, and an unmatched knowledge of relevant pharmaceutical product testing, development and packaging. west supports customers from sales, manufacturing, and research and development locations in north and south america, europe, asia and australia.

Organization
West Pharmaceutical Services Inc
Employees
10600
CEO
Mr. Eric M. Green
Industry
Health Technology

FAQs